In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in oncology, the challenges and rewards of moving to Abu …
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to…
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid…
The FDA approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [combined positive score ≥…
In a phase III trial (OASIS-4) reported at the 2025 Annual ASCO Meeting and in the New England Journal of Medicine, Cardoso et al attempted…
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARAN OTE trial, which evaluated the androgen…
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared…
